Progress of clinical laboratory tests and molecular imaging for diagnosis of Alzheimer's disease
10.3760/cma.j.issn.1009-9158.2020.03.025
- VernacularTitle:阿尔茨海默病的实验室检测与分子影像学检查的研究进展
- Author:
Wenbo ZHU
1
;
Qinfeng XU
;
Jingjing LI
;
Kui ZHANG
;
Bing BAI
Author Information
1. 南京大学医学院附属鼓楼医院检验科，南京 210008
- From:
Chinese Journal of Laboratory Medicine
2020;43(3):328-335
- CountryChina
- Language:Chinese
-
Abstract:
With the expansion of aging population, Alzheimer′s disease (AD) is increasingly imposing a substantial burden on the society. Because of irreversible neuronal death in the brain, effective control of AD relies on early diagnosis for timely therapeutic intervention, and this requires efficient laboratory tests and molecular imaging. Current laboratory tests for AD includes measurements of Aβ peptides, Tau, and a number of other recently discovered molecules in the cerebrospinal fluid and the peripheral blood. PET-based imaging of glucose metabolism, amyloid Aβ, Tau neurofibrillary tangles, TSPO protein, and neuronal receptors, has also proven to be useful in clinical finding of AD. This review will focus on the progress in studies of these biomarkers and methodologies for ADdiagnosis.
